| www.bioportfolio.com |
http://www.bioportfolio.co.uk/bulletin_42.htm
June
8 2004
|
|
|
|
|
In
this Week's issue:
1) Dovebid
- major sale of Genomic Research and
Lab Equipment -
see above
2) Dovebid - major sale of Lab
Equipment Ultra-Modern Biopharmaceutical Research and Development Facility
3) BIOPHEX - 2004 Conference - Sept
28th to 30th - from
post discovery to market
4) Biotechnology
Management Practices - get
your management right to prosper!
5) Reuters
Business Insight - Buy
one get one free special offer - Pharmaceutical
Portfolio Management
6) BioAnnouncement - 50,000 emails to prospective customers in
the life science space
|
|
| VIROPHARMA
Webcast Auction 9th June |
|
|
|
VIROPHARMA
AUCTION Private Treaty Sale Followed By a 1-Day Webcast Auction of Lab
Equipment at a 100,000 Square Foot Ultra-Modern Biopharmaceutical Research
and Development Facility. Webcast Auction Wednesday, June 9, 2004
Beginning at 9:00 AM (ET). Bid Live in Exton, PA or on DoveBid's website: www.dovebid.com.
For more information, visit our website or call 800-665-1042.
http://www.dovebid.com/Auctions/AuctionDetail.asp?auctionID=2554&referraltag=viro1b
|
| BIOPHEX
2004 Conference - from post-discovery to market |
 |
|
BIOPHEX
delivers a unique perspective on the strategic and managerial issues that
affect everyone in post-discovery development and manufacturing. The
conference, produced by Genetic Engineering News, is targeted to help
top-level biopharmaceutical professionals successfully transition their drug
from post-discovery to market. For more information open:
http://www.biophex.com.
|
| Biotechnology
Management Practices |
 |
|
Mardis
Aibel have performed a unique study:
- the first objective look at the role of
management in the US Biotechnology Industry
- views from within, from biotech industry
specialists and the investment community
- identifying the practices that work and
those that don’t highlighting the unique management challenges biotech
industry faces
Most business executives would argue
that companies lacking basic management skills are unlikely to succeed in
the marketplace or generate significant returns for shareholders.
Nevertheless, both managers and investors in numerous biotechnology firms
seem to believe that this standard wisdom does not hold true for them.
Research completed last year by Mardis,
Aibel & Associates shows that a substantial portion of biotech
executives view “achieving operational excellence” as a secondary
concern. Many report that a significantly higher priority is “validating
the scientific concept”, “searching for funding” or “publicizing the
work of the firm”. Similarly, many biotech investors quietly acknowledge
that they care less about creating firms with viable management models than
in pushing firms to the next news announcement that will drive a jump in
valuation. The all-too-common belief for many in the industry is that, for
biotech's, first-class management is not needed to achieve world-class
returns.
They are wrong.
For more information open:
|
| Reuters
Business Insight OFFER - Buy
one get one free special offer |
|
|
|
Pharmaceutical
Portfolio Management: Integrated decision-making in marketing and R&D,
is a strategic management report that presents a comprehensive overview of
effective portfolio management processes, with a focus on better preparing
senior management, R&D and marketing executives for integrated
decision-making across the organization as a whole. Use this report to
improve product lifecycle decisions and ensure the right people are involved
in making the right decisions, at the right time.
June
Promotion – SAVE £745/€1199/$1199
Purchase the ‘Pharmaceutical
Portfolio Management’ report before Friday 11th June 2004, and
receive a FREE report of your choice from the list below:
Choose your free report
from the list below:
-
The Pharmacoeconomics
Outlook
-
The Pharmaceutical
Sales Force Outlook
-
Pharmaceutical
Regulatory Affairs Outlook
-
The Pharmaceutical
Industry Paradox
-
Pharmaceutical
Strategic Alliances
-
The Top 12
Pharmaceutical Companies
-
The Women’s Health
Outloook to 2008
-
The Cancer Outlook to
2008
-
The Cardiovascular
Outlook to 2008
-
The CNS Outlook to
2008
-
The Antivirals
Outlook to 2007
-
The DTC Marketing
Outlook 2003
-
The Biotech Sector in
the Post-Genomic Era
-
New Cancer
Therapeutics
-
Pharmaceutical
R&D Outsourcing Strategies
-
The Lifestyle Drugs
Outlook to 2007
-
Next Generation Drugs
-
Opportunities in
R&D
Reuters Business
Insight reports are published by Datamonitor, in association with Reuters.
Reuters, the sphere logo and Reuters Business Insight are trade marks of the
Reuters group of companies around the world and are used by Datamonitor
under licence from Reuters.
To order email peter.barfoot@bioportfolio.com
or purchase online at:
http://www.bioportfolio.com/cgi-bin/acatalog/Reuters_2003.html#a153
|
| BioAnnouncements
- promoting technology to the life science sector |
| Do you have
technology that you wish to license?
Do you want to contact 50,000 life science
users?
Complete the online enquiry form - click
here!
|
|
In
2004, LeadDiscovery & BioPortfolio, two of the largest
drug development information providers combined their resources to launch BioAnnouncements.
Through this service, LeadDiscovery distributes dedicated mail shots
announcing licensing opportunities and R&D services to the drug
discovery community.
Interested? Email: leaddiscovery@leaddiscovery.co.uk
Read more: http://www.leaddiscovery.co.uk/adpage.html
|
Contact
us:
Editorial and features: peter.barfoot@bioportfolio.com
Subscriber
information:
To subscribe for the
BioPortfolio Bulletin in HTML, email:
bioportfolio-subscribe-request@peach.ease.lsoft.com
To unsubscribe,
email: bioportfolio-signoff-request@peach.ease.lsoft.com
WITH NO SUBJECT. The system will automatically remove your email
address from the list based on your email address. If your email has
changed please email peter.barfoot@bioportfolio.com
with a list of your email address and we will manually unsubscribe for you.
Thank you for your understanding.
©2004
BioPortfolio Limited
|
|
